NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
NRXP$2.36-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $6,199 | $13,371 |
| General and administrative | 13,505 | 14,216 |
| Settlement (income) expense | (1,202) | 250 |
| Total operating expenses | 18,502 | 27,837 |
| Loss from operations | (18,502) | (27,837) |
| Other (income) expenses: | ||
| Interest income | (44) | (494) |
| Interest expense | 230 | 120 |
| Convertible note default penalty | 849 | — |
| Change in fair value of convertible note payable | 2,654 | 2,707 |
| Change in fair value of warrant liabilities | 1,657 | (20) |
| Loss on convertible note redemptions | 1,278 | — |
| Total other expenses, net | 6,624 | 2,313 |
| Net loss | (25,126) | (30,150) |
| Deemed dividend - warrants | — | (9) |
| Net loss attributable to common stockholders | $(25,126) | $(30,159) |
| Comprehensive loss: | ||
| Net loss | (25,126) | (30,150) |
| Change in fair value of convertible note attributed to credit risk | — | 3 |
| Comprehensive loss | $(25,126) | $(30,153) |
| Net loss per share: | ||
| Basic and diluted | $(2.36) | $(3.98) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 10,644,461 | 7,576,176 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.